TY - JOUR T1 - Preclinical Evaluation of Adoptive Cell Therapy for Patients with Metastatic Renal Cell Carcinoma JF - Anticancer Research JO - Anticancer Res SP - 145 LP - 154 VL - 29 IS - 1 AU - GAL MARKEL AU - TALI COHEN-SINAI AU - MICHAL J. BESSER AU - KFIR OVED AU - ORIT ITZHAKI AU - RACHEL SEIDMAN AU - AVRAHAM J. TREVES AU - EDUARD FRIDMAN AU - YONA KEISARI AU - ZOHAR DOTAN AU - JACOB RAMON AU - JACOB SCHACHTER Y1 - 2009/01/01 UR - http://ar.iiarjournals.org/content/29/1/145.abstract N2 - Background: Interleukin-2 (IL-2) shows encouraging clinical results in metastatic renal cell carcinoma (RCC) patients, but is limited by substantial toxicity. Cell-based therapy holds a promise, but past attempts in RCC were unsuccessful. Advances in tumor-infiltrating lymphocytes (TIL) generation technology and modified clinical protocols recently yielded a 50% response in refractory melanoma patients. Materials and Methods: RCC-derived TIL and tumor cells were processed by current protocols from tumor specimens in a clean laboratory. The expanded TIL were characterized and tested in functional assays. Results: The TIL cultures were efficiently generated and massively expanded. Virtually all the expanded cells were T-cells, but a considerable variability in the CD4/CD8 ratio and a frequent CD4-CD8- phenotype were observed. The TIL exerted cytotoxic or IFNγ-release activities against autologous targets in major histocompatibility (MHC) class I-restricted and -independent functional patterns. The functional results were superior to former technologies. Conclusion: Recent developments in TIL generation technology and clinical patient conditioning protocols indicate that the TIL-based approach for RCC could be revisited. Copyright© 2009 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved ER -